Kell blood group metallo-endopeptidase (KEL)

The Kell blood group metallo-endopeptidase, commonly known as the Kell antigen or CD238, is a type II transmembrane glycoprotein expressed primarily on the surface of erythrocytes and their precursors. It functions as a zinc-dependent endopeptidase capable of cleaving big endothelin-3 to produce the potent vasoconstrictor endothelin-3, though its physiological role in systemic blood pressure regulation remains secondary to other enzymes. The Kell protein is covalently linked via a disulfide bond to the XK protein; the absence of this complex leads to McLeod syndrome, characterized by acanthocytosis and neurological defects. In clinical medicine, the Kell system is highly significant due to its potent immunogenicity. Anti-Kell antibodies are a leading cause of severe hemolytic disease of the fetus and newborn (HDFN), where they cause anemia not only through hemolysis but also by suppressing fetal erythropoiesis. While not a traditional target for small-molecule drugs, it is a critical target for immune-mediated pathologies and a major consideration in transfusion medicine and maternal-fetal care.

Other names

CD238Kell blood group glycoproteinKell blood group, metallo-endopeptidaseEndothelin-3-converting enzymeECE-3

Therapeutic interventions typically involve the administration of intravenous immunoglobulin (IVIG) to neutralize maternal anti-Kell antibodies or the use of monoclonal antibodies like Daratumumab, which can inadvertently bind to CD38 on red blood cells and interfere with Kell-related blood bank testing. Direct targeting of the Kell protein for therapeutic inhibition is not a standard clinical practice; rather, management focuses on mitigating the immune response against the antigen.